|

Saruparib Clinical Trials

5 actively recruiting trials across 5 locations

Also known as: 2589531-76-8, AZD 5305, AZD-5305, AZD5305, PARP Inhibitor AZD5305

Pipeline

Early 1: 1Phase 2: 1Phase 3: 2Phase 1/2: 1

Top Sponsors

  • AstraZeneca3
  • SWOG Cancer Research Network1
  • OHSU Knight Cancer Institute1

Indications

  • Cancer5
  • Locally Advanced Pancreatic Ductal Adenocarcinoma1
  • Lung Small Cell Carcinoma, P Subtype1
  • Lung Small Cell Carcinoma, N Subtype1
  • Lung Small Cell Carcinoma, I Subtype1

Chandler, Arizona1 trial

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

Research Site

Phase 3

Phoenix, Arizona1 trial

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Research Site

Phase 3

Newark, Delaware1 trial

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Helen F Graham Cancer Center

Phase 2

New York, New York1 trial

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

Research Site

Phase 1/2

Portland, Oregon1 trial

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

OHSU Knight Cancer Institute

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.